
Wednesday, March 12, 2025 8:40:32 AM
Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the "Phase 1").
https://www.otcmarkets.com/stock/HMTXF/news/Hemostemix-and-FireFly-Neurosciences-Brain-Network-Analytics-BNATM-Engage-to-Complete-Phase-1-Vascular-Dementia-Clinical?id=469780
Recent HMTXF News
- Financing & Partnership News Send Shares of this Stem-Cell Therapy Company on a Tear • AllPennyStocks.com • 06/03/2024 05:35:00 PM
7.2 MW Glor Rd Solar Project in Development by SolarBank in New York • GY2 • Apr 29, 2025 9:06 AM
Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology • AVAI • Apr 29, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer • BLO • Apr 28, 2025 8:49 AM
Veri Medtech (VRHI) Retains PCAOB Auditor • VRHI • Apr 28, 2025 8:30 AM
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • COEP • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM